+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Gazyva"

Chronic Lymphocytic Leukemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Thumbnail Image

Chronic Lymphocytic Leukemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • May 2024
  • 133 Pages
  • Global
From
B Cell Chronic Lymphocytic Leukemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Thumbnail Image

B Cell Chronic Lymphocytic Leukemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • May 2024
  • 131 Pages
  • Global
From
Global Leukemia Antibodies Market, Drug Sales & Clinical Trials Insight 2028 - Product Thumbnail Image

Global Leukemia Antibodies Market, Drug Sales & Clinical Trials Insight 2028

  • Report
  • May 2022
  • 330 Pages
  • Global
From
Gazyva Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Gazyva Emerging Drug Insight and Market Forecast - 2032

  • Report
  • August 2022
  • 30 Pages
  • Global
From
Chronic Lymphocytic Leukemia (CLL) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032 - Product Thumbnail Image

Chronic Lymphocytic Leukemia (CLL) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032

  • Report
  • September 2023
  • 65 Pages
  • Global
From
Gazyva - Product Thumbnail Image

Gazyva

  • Report
  • January 2019
  • 40 Pages
  • Global
From
  • 6 Results (Page 1 of 1)
Loading Indicator

Gazyva is a type of drug used to treat certain types of leukemia, a type of cancer of the blood and bone marrow. It is a monoclonal antibody, which means it is designed to target and destroy cancer cells. Gazyva works by blocking a protein called CD20, which is found on the surface of certain types of leukemia cells. By blocking this protein, Gazyva prevents the cancer cells from growing and dividing. Gazyva is approved for use in combination with chemotherapy to treat chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). It is also approved for use in combination with bendamustine to treat CLL. Gazyva is manufactured by Roche, a Swiss pharmaceutical company. Other companies in the market include AbbVie, AstraZeneca, Bristol-Myers Squibb, and Novartis. Show Less Read more